Ergothioneine: The Longevity Vitamin That Forgot to Run a Trial

A vitamin nobody named until recently

Every few years the longevity internet crowns a new molecule, and in 2026 the crown landed on a compound most people cannot pronounce. Ergothioneine — a sulfur-containing amino acid your body cannot make and gets almost entirely from mushrooms — has moved from an obscure line in food-science journals to a headline ingredient in premium supplement stacks.¹⁰ The branded version, MitoPrime, now appears in products from a dozen labels, and the pitch is remarkably consistent: this is the "longevity vitamin," the one your ancestors got from foraged fungi and your seed-oil diet has starved you of.

The narrative has unusually respectable scaffolding. A celebrated Berkeley biochemist gave it the "longevity vitamin" label in a 2018 paper.⁵ A 21-year Swedish cohort study found that people with more of it in their blood died less.¹ Your body maintains a dedicated transporter whose apparent only job is to hoard the stuff. Put those three facts on a product page and you have a compelling story. The question this issue asks is the one the product pages skip: does taking ergothioneine actually do anything, or is it simply the tidiest blood marker for eating your vegetables that science has ever found?

The molecule with its own front door

Ergothioneine is not made by human cells, or by any animal cell. It is synthesized by certain fungi and bacteria, which means everything in your bloodstream ultimately traces back to something that grew in soil.¹⁰ That alone would make it a dietary curiosity. What makes it interesting is the front door.

In 2005, Dirk Gründemann's group discovered that a previously mysterious membrane protein called OCTN1, encoded by the gene SLC22A4, exists largely to transport ergothioneine into cells with high selectivity.⁶ Biology is thrifty. When an organism maintains a specialized, high-affinity transporter for a single dietary compound, and concentrates that compound in tissues under heavy oxidative stress — the liver, the kidneys, red blood cells, the lens of the eye, parts of the brain — it is at least suggestive that the compound is doing something worth the metabolic rent.¹¹

What it plausibly does, in the laboratory, is act as a cytoprotectant. In cell and animal models it scavenges hydroxyl radicals and singlet oxygen, chelates metals, and appears to shield mitochondria from oxidative damage.¹¹ This is the mechanistic bedrock of the entire longevity pitch. It is also almost entirely preclinical. A transporter that retains a molecule tells you the body values it. It does not tell you that swallowing more of it changes how long or how well you live. Those are different claims, and the distance between them is where this whole story lives.

The framing that launched the hype came from Bruce Ames, who in 2018 proposed a category he called "longevity vitamins": nutrients not required to prevent an acute deficiency disease like scurvy or rickets, but plausibly required for long-term health, where a shortfall quietly raises your risk of age-related disease decades later.⁵ He nominated ergothioneine as a leading candidate. Read carefully, that paper is a hypothesis — a well-reasoned, testable proposal about what we should investigate. Read on a supplement label, it becomes a settled designation. It is neither an official vitamin nor an established requirement.

The 21-year curve everyone quotes

The single most-cited piece of evidence, and the reason the word "mortality" appears in nearly every marketing deck, is a 2020 study in the journal Heart.¹ Researchers analyzed blood from 3,236 adults in the Swedish Malmö Diet and Cancer cohort who were free of cardiovascular disease and diabetes at the start, then followed them for a median of 21.4 years. Ergothioneine turned out to be one of the metabolites most strongly associated with survival.

The cognitive data run in the same direction. In a Singapore memory-clinic cohort of 470 older adults, lower baseline ergothioneine predicted worse cognition and faster decline across memory, executive function, attention, and language, alongside more white-matter damage on imaging.⁴ Blood levels of the compound fall with age, and are conspicuously low in people with frailty, mild cognitive impairment, Parkinson's, and dementia.⁹ From this, the Halliwell group has floated a "healthy" threshold and a picture in which declining ergothioneine is an early, silent step toward age-related disease.

Take the epidemiology on its own terms and it is genuinely impressive: large samples, long follow-up, consistent direction, biological plausibility, replication across continents and across different diseases. This is more than most viral supplements can dream of. And it is also exactly the shape that some of the most expensive failures in nutrition science took right before they collapsed.

Two trials, and the bigger one said no

Here is where the marketing goes quiet, because the interventional human evidence — the studies where you actually give people ergothioneine and see what happens — amounts to two trials, and the better-designed one missed its primary endpoint.

The authors of the larger trial are candid about why it may have fallen flat: participants started with already-healthy ergothioneine levels, leaving little room to improve, and 16 weeks may be far too short to move a process that unfolds over decades.³ Those are reasonable defenses. They are also the same reasonable defenses offered for every supplement whose confirmatory trial disappoints. The honest summary is blunt. There is not a single adequately powered human trial showing that ergothioneine supplementation improves a hard outcome — not mortality, not cardiovascular events, not dementia. The one properly sized cognition trial we have said no on the thing it set out to measure.

Why "low blood level predicts disease" keeps fooling us

Ergothioneine has a problem that no amount of transporter biology can wave away: it is a nearly perfect marker of eating well. It comes from mushrooms, whole grains, and whole foods, so the people with high blood levels are, almost by construction, the people with better diets, more money for fresh food, and healthier lives overall.^1,10 When such a person also lives longer, you cannot tell whether the ergothioneine helped or whether it was just riding along with everything else that mushroom-eaters tend to do right.

We have run this exact experiment before, at enormous cost. Beta-carotene was strongly associated with lower cancer rates in observational studies — until randomized trials gave it to smokers and found it increased lung cancer. Vitamin E looked cardioprotective in cohorts and did nothing, or slightly worse, in trials. Time and again, "low blood level of a food-derived antioxidant predicts disease" turned out to mean "people who eat poorly get sick," not "here is a deficiency you can fix from a bottle." Ergothioneine fits that template with almost uncomfortable precision.

None of this makes the hypothesis wrong. It makes it unproven, and unproven in a specific, familiar, humbling way. The only instrument that can separate a causal nutrient from a diet-quality shadow is a randomized controlled trial with a real clinical endpoint. For ergothioneine, that trial has not been run. What we have instead is a strong correlation and a manufacturer's cognition study that came up empty.

The least controversial part of the story

If the efficacy case is shaky, the safety case is reassuringly solid — which matters, because it changes the risk calculus for anyone tempted to try it anyway. Synthetic L-ergothioneine holds GRAS status with the FDA and was approved as a novel food in Europe.⁷ European regulators set a no-observed-adverse-effect level of 800 mg per kilogram per day from rat studies, found no genotoxicity concern, and authorized supplemental doses of 30 mg per day for adults — later extending approvals to children and to pregnant and breastfeeding women, with safety margins in the hundreds.^7,8

The human trials, small as they are, reported no adverse events and no signs of liver or kidney stress; the 2025 study even noted modest reductions in liver enzymes and no rise in TMAO, a metabolite tied to cardiovascular risk.³ The compound has an unusually long half-life, lingering in tissue for weeks rather than clearing in hours. So the practical safety verdict is easy: at supplement doses, ergothioneine appears benign. The catch is that "unlikely to hurt you" and "shown to help you" are not the same finding, and only one of them is on the label.